论文部分内容阅读
目的初步探讨强肝丸抗肝纤维化的药理作用。方法Wistar大鼠随机分成3组,即正常对照组、模型组、强肝丸治疗组。采用腹腔注射四氯化碳(CCl4)橄榄油混合液的方法制备肝纤维化动物模型。治疗组采用预防给药的方式,造模结束后持续治疗4周。治疗结束后,动物麻醉,取肝组织,进行羟脯氨酸含量检测、HE染色、Mallory染色及Ⅰ型胶原(CoL I)免疫组织化学染色。结果与模型组比较,强肝丸能显著降低肝组织中羟脯氨酸水平(P<0.01),减少肝组织中总胶原的合成和沉积(P<0.05),下调肝组织中Ⅰ型胶原(CoL I)的表达(P<0.05)。结论强肝丸对肝组织中胶原蛋白的合成过程有显著抑制作用,从而阻断肝纤维化的病理过程。
Objective To explore the pharmacological effects of Qianggan Pill on hepatic fibrosis. Methods Wistar rats were randomly divided into 3 groups: normal control group, model group and Qianggan Pills treatment group. Liver fibrosis animal models were prepared by intraperitoneal injection of carbon tetrachloride (CCl4) olive oil mixture. The treatment group was treated with prophylaxis and the treatment lasted for 4 weeks after the model was completed. After the treatment, animals were anesthetized and liver tissues were taken for hydroxyproline content detection, HE staining, Mallory staining, and type I collagen (CoI) immunohistochemical staining. Results Compared with the model group, Qianggan Pill can significantly reduce the level of hydroxyproline in the liver (P<0.01), decrease the synthesis and deposition of total collagen in liver tissue (P<0.05), and down-regulate type I collagen in liver tissue ( Expression of CoL I) (P < 0.05). Conclusion Qianggan Pill has a significant inhibitory effect on the synthesis of collagen in liver tissue, thus blocking the pathological process of hepatic fibrosis.